EcoDrugPlus

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSSAUG00010003104
Gene Symbol: F2RL3
3 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSSAUG00010026031
Gene Symbol: FAUA
1 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSSAUG00010002435
Gene Symbol: FYNA
1 Cross references
191 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSSAUG00010011947
Gene Symbol: GPR119
1 Cross references
174 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSSAUG00010004842
Gene Symbol: HCK
1 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSSAUG00010027270
Gene Symbol: ITK
1 Cross references
205 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSSAUG00010011966
Gene Symbol: IMPDH1B
1 Cross references
257 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSSAUG00010010552
Gene Symbol: JAK1
3 Cross references
212 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSSAUG00010025076
Gene Symbol: KITB
1 Cross references
200 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSSAUG00010004376
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSSAUG00010006309
Gene Symbol: MALT1
2 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSSAUG00010005907
Gene Symbol: MAPKAPK2
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).